Form 4 for LMAT LEMAITRE VASCULAR INC
Accepted 2023-05-11 00:00:00 ET · period of report 2023-05-09 · accession 0001437749-23-013936 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-05-11 | 2023-05-09 | LMAT | Jasinski Lawrence J | Dir | S - Sale+OE | $66.00 | -3,648 | 9,310 | -28% | -$240.8K |
| DM | 2023-05-11 | 2023-05-09 | LMAT | Jasinski Lawrence J | Dir | M - OptEx | $39.61 | +3,648 | 11.8K | +45% | +$144.5K |
| DM | 2023-05-11 | 2023-05-09 | LMAT | Jasinski Lawrence J | Dir | M - OptEx | $0.00 | -3,648 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-09 | S | D | 3,648 | $66.00 | 9,310 | D | — | — | |
| 2 | Common | Common Stock | 2023-05-09 | M | A | 1,148 | $48.60 | 12,958 | D | — | — | (F1) Represents shares acquired upon exercise of options by the Reporting Person, as reported in Table II. |
| 3 | Common | Common Stock | 2023-05-09 | M | A | 2,500 | $35.48 | 11,810 | D | — | — | (F1) Represents shares acquired upon exercise of options by the Reporting Person, as reported in Table II. |
| 4 | Derivative | Stock Option (Right to Buy) | 2023-05-09 | M | D | 1,148 | $0.00 | 2,296 | D | $48.60 · 2021-12-11 to 2026-12-11 | 1,148 Common Stock | (F3) Represents a stock option award that vests on a time-based schedule as follows: 33 1/3% of the award vests on the anniversary of the grant date listed in the table, with the balance besting in equal annual installments over the remaining two years. |
| 5 | Derivative | Stock Option (Right to Buy) | 2023-05-09 | M | D | 2,500 | $0.00 | 0 | D | $35.48 · 2019-12-20 to 2024-12-20 | 2,500 Common Stock | (F2) This option is fully vested and exercisable. |